In order to evaluate the efficacy and safety of @entity10438 nasal spray (MFNS) in @entity1 with @entity9590 ( @entity9590 ) a phase III, double-blind, randomized, placebo-controlled, Nordic multicenter study was performed at 16 sites (7 in Sweden, 3 in Denmark, 3 in Finland and 3 in Norway). A total of 329 @entity1 (age 18-82 years) with a mean duration of @entity9590 of 9 years were included in the study. The total duration of the study was 11 weeks: 2 weeks of screening, 6 weeks of treatment and 3 weeks of follow-up. Inclusion criteria were unspecific @entity2490 and exclusion criteria were a positive skin prick test as well as intolerance to @entity117 or non-steroidal anti-inflammatory drugs. Endoscopy was performed to exclude @entity1 with @entity11578 and @entity480 . The primary efficacy variable was the subject's total overall evaluation. In the intention-to-treat (ITT) group of @entity1 (n = 329) the improvement rates were 56% (MFNS) and 49% (placebo). In the per-protocol (PP) group (n = 251) the corresponding figures were 58% and 47%. Stratifying for groups of @entity1 having moderate symptoms, the results were 54% vs 43% in the ITT group and 56% vs 41% in the PP group. The therapeutic response showed greater improvement in total nasal score as recorded by the investigator in the groups treated with MFNS as compared to the placebo group (p = 0.09 [PP], p = 0.14 [ITT]). Adverse events occurred during the study, @entity1729 and @entity10 being the most frequently reported, but there was no statistically significant difference between MFNS and placebo. The results of this study indicate that MFNS is a safe and effective treatment for @entity1 with @entity9590 .

@entity10438 nasal spray in the treatment of XXXX : a nordic, multicenter, randomized, double-blind, placebo-controlled study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity11578 :: ('MESH:D020914', 'Disease') :: ['structural anomalies'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity2490 :: ('MESH:D012220', 'Disease') :: ['rhinitis symptoms'] @entity1729 :: ('MESH:D012141', 'Disease') :: ['upper respiratory tract infections'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache'] @entity480 :: ('MESH:D009298', 'Disease') :: ['nasal polyps'] @entity9590 :: ('MESH:D012221', 'Disease') :: ['PNAR', 'perennial non-allergic rhinitis'] @entity10438 :: ('MESH:C053915', 'Chemical') :: ['mometasone furoate']
@entity9590 :: (MESH:D012221,Disease) :: ['perennial non-allergic rhinitis']
